JOURNAL CLUB


https://doi.org/10.5005/imcr-11021-0002
Integrative Medicine Case Reports
Volume 5 | Issue 2 | Year 2024

Activation of TrkB–Akt Signaling Rescues Deficits in a Mouse Model of SCA6


Jyotsna Sharma

Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Corresponding Author: Jyotsna Sharma, Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, Phone: +91 8544765971, e-mail: jyotsnasharma601@gmail.com

How to cite this article: Sharma J. Activation of TrkB–Akt Signaling Rescues Deficits in a Mouse Model of SCA6. Integr Med Case Rep 2024;5(2):70–71.

Source of support: Nil

Conflict of interest: None

Received on: 10 July 2024; Accepted on: 07 August 2024; Published on: 24 October 2024

Keywords: Brain derived neurotrophic factor, Exercise, Spinocerebellar ataxia.

INTRODUCTION

Spinocerebellar ataxia 6 is a rare neurodegenerative disease caused by cytosine, adenine, guanine (nucleotide) (CAG) repeat expansion mutation in CACNA1A gene.1 Mutation in the CACNA1A gene leads to a protein abnormality. This disease impairs the muscle coordination typically starting in middle age. Currently, there is no treatment available for SCA6.2 Previous studies have shown that the mice model of SCA6 develops muscle dysfunction at the age of 7 months and Purkinje cell loss at the age of 2 years.3 These studies suggested that there is time gap between the onset of neuron loss and muscle coordination deficit. Therefore, it might be possible that early motor coordination impairments occur due to cerebellar function instead of cell death in patients with SCA6. Furthermore, this disease might be reversible by rescuing cerebellar function before the degeneration of Purkinje cells.

Neurotrophic factors like brain derived neurotrophic factor (BDNF) play an important role in the survival and development of the nervous system.4 Previous studies have shown that there is a reduction in the level of BDNF in the cerebellum of postmortem SCA6 patients and several mouse models of SCA6.5 Therefore, it might be possible that BDNF signaling deficit play a role in pathophysiology of SCA6.

Exercise has a positive impact on the overall health of the individual. Exercise found to play a neuroprotective role by increasing the level of BDNF which leads to the enhancement of hippocampal neurogenesis.6

Hence, this study aimed to investigate the effect of exercise-induced BDNF singling pathway on the pathophysiology of SCA6 mouse model and supplementation of 7,8-dihydroxyflavone (7,8-DHF) an agonist of TrkB, can reverse the disease pathology.

STUDY DESIGN

All experiments were formed after getting approval from McGill Animal Care Committee according to Animal Care guidelines provided by the Canadian Council. A knock-in mice model of SCA6 with 84 CAG repeat expansion at CACNA1A locus was included in the study. Mice were allowed to perform voluntary running using running wheels in cages and were acclimatized to exercise on the treadmill. The treadmill exercise was provided for 6 weeks (Fig. 1), 20 min daily with speed of 6 m/min for 5 minutes, 10 m/min for 5 minutes, and 1 m/min for 5 minutes. In some cases, SCA6 mice were compared with wild-type, and in another, in order to examine the role of BDNF-TrkB signaling pathway at the onset and progression of SCA6, the following experiments were performed:

Fig. 1: Schematic of exercise regimen and 7,8-DHF administration

RESULTS

IMPLICATION

This study has shown improvement in motor coordination, Purkinje cell firing deficit via activation of TrkB–Akt pathway after administration of 7,8-DHF in SCA6 mouse. So, 7,8-DHF can as potential therapeutic drug for SCA6. This study indicates that drugs which target TrkB–Akt signaling pathway may be beneficial for the treatment of SCA6 in humans. Furthermore, TrkB–Akt pathway may be a potential therapeutic target for SCA6.

REFERENCES

1. Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nature genetics 1997;15(1):62–69. DOI: 10.1038/ng0197-62.

2. Solodkin A, Gomez CM. Spinocerebellar ataxia type 6. Handbook of Clinical Neurology 2012;103:461–473. DOI: 10.1016/B978-0-444-51892-7.00029-2.

3. Jayabal S, Ljungberg L, Erwes T, et al. Rapid onset of motor deficits in a mouse model of spinocerebellar ataxia type 6 precedes late cerebellar degeneration. Eneuro 2015;2(6). DOI: 10.1523/ENEURO.0094-15.2015.

4. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nature Rev Neurol 2009;5(6):311–322. DOI: 10.1038/nrneurol.2009.54.

5. Takahashi M, Ishikawa K, Sato N, et al. Reduced brain‐derived neurotrophic factor (BDNF) mRNA expression and presence of BDNF‐immunoreactive granules in the spinocerebellar ataxia type 6 (SCA6) cerebellum. Neuropathology 2012;32(6):595–603. DOI: 10.1111/j.1440-1789.2012.01302.x.

6. Liu PZ, Nusslock R. Exercise-mediated neurogenesis in the hippocampus via BDNF. Front Neurosci 2018;12:52. DOI: 10.3389/fnins.2018.00052.

________________________
© The Author(s). 2024 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.